NCT06853925 Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
| NCT ID | NCT06853925 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Georgetown University |
| Condition | Thyroid Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2025-10-02 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 88 participants in total. It began in 2025-10-02 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if adult patients diagnosed with differentiated thyroid cancer can easily use and benefit from an online tool aimed to provide patients with educational resources and symptom management strategies to improve their quality of life after radioactive iodine (RAI) treatment. The main questions it aims to answer are: 1. Can patients easily use and benefit from the RAI Support intervention? 2. Does RAI Support improve health-related quality of life (overall well-being) compared to usual care? This research will help test better digital tools to support thyroid cancer survivors in managing their health after RAI treatment. Researchers will compare RAI Support to treatment as usual (a publicly available informational website about thyroid cancer) to see if RAI Support works to improve patients' overall well-being. Participants will: 1. Receive access to RAI Support or an informational website (treatment as usual) for four weeks. 2. Use the assigned website once a week for up to four weeks. 3. Complete two online questionnaires (an initial questionnaire and a final questionnaire after four weeks of using the assigned website) about symptoms related to RAI treatment, mood, and confidence in managing symptoms. 4. Complete an optional 60 minute virtual interview about your experiencing using the assigned website.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older (papillary or follicular carcinoma) * Diagnosed with differentiated thyroid cancer * Received radioactive iodine (RAI) treatment less than or equal to three years ago. * Mild to moderate symptoms of RAI * Able to provide informed consent in English * Access to a computer, tablet, or smartphone with internet connectivity Exclusion Criteria: * A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.
Contact & Investigator
Alaina Carr, PhD
PRINCIPAL INVESTIGATOR
Georgetown University
Frequently Asked Questions
Who can join the NCT06853925 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thyroid Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06853925 currently recruiting?
Yes, NCT06853925 is actively recruiting participants. Contact the research team at cancercarestudy@georgetown.edu for enrollment information.
Where is the NCT06853925 trial being conducted?
This trial is being conducted at Washington D.C., United States.
Who is sponsoring the NCT06853925 clinical trial?
NCT06853925 is sponsored by Georgetown University. The principal investigator is Alaina Carr, PhD at Georgetown University. The trial plans to enroll 88 participants.